News research shows GLP-1 medications may help treat a wide range of conditions, from addiction and dementia to heart disease and psychotic disorders.

A new study compares the benefits and risks of taking GLP-1 medications for weight loss, including risks of dementia, addiction, heart disease, and gastrointestinal problems, among others.

Popular GLP-1 medications approved for weight loss, diabetes, and heart disease may have untapped potential to reduce the risks of substance abuse disorders, psychosis, infections, some kinds of cancer and dementia,

GLP-1 medications linked to a lower risk of dementia and addiction but higher risk of kidney, pancreatic, and gastrointestinal issues. Demand for weight-loss medications, including popular brands like Ozempic and Wegovy,

Over 2 million people were included in new research to test these drugs against 175 different health outcomes.

T he newest weight-loss drugs, Wegovy and Zepbound, are incredibly popular. But doctors are still learning about all of the ways they affect the body—both helpful and harmful—beyond reducing weight. In report published in Nature Medicine,

A new study highlighted Monday the potential benefits of popular diabetes drugs on a wide range of health issues including dementia and cardiovascular diseases, although experts warned against seeing them as miracle drugs.

Research shows that people who take these weight-loss medications may have a lower risk of dementia and numerous other health conditions.

Weight-loss jabs could be linked to lower risk of several conditions including stroke and dementia - Researchers said weight-loss drugs could affect health in eye-opening ways, but other experts say m

GLP-1 weight loss drugs - such as Wegovy and Mounjaro - may reduce risk of conditions including Alzheimer’s disease and dementia.

Dr. Anelyssa D'Abreu, an associate professor of neurology in UVA's School of Medicine who specializes in geriatric neurology, talked with UVA Today about the newest study and shared ways people can reduce their risk of developing dementia, most often linked to Alzheimer's disease.